Respiratory Today—March 6, 2026

This weekly update in Respiratory highlights a mix of late-stage clinical readouts, early- to mid-stage development progress, observational research, and conference-linked data presentations. Coverage also includes vaccine platform funding and diagnostic innovation, reflecting continued activity across therapeutic, preventive, and care-enabling approaches.

In Today’s Newsletter

Dive deeper

🫁 Gossamer Bio posts Phase 3 PROSERA topline for seralutinib in PAH [1] [US • 23 Feb 2026]

https://ir.gossamerbio.com/news-releases/news-release-details/gossamer-bio-announces-topline-results-phase-3-prosera-study
Context: Phase 3 PROSERA evaluated seralutinib in pulmonary arterial hypertension, with Week 24 six-minute walk distance as the primary endpoint; subgroup details and safety were also reported [1].
Key point: Gossamer Bio said seralutinib improved six-minute walk distance versus placebo, but the overall-population primary endpoint did not meet the prespecified alpha threshold (despite nominal p < 0.05) [1].
Implication: May influence prescriber choice and payer reviews pending full data.

👃 Upstream Bio to present added Phase 2 VIBRANT analyses for verekitug in CRSwNP [2] [US • 26 Feb 2026]

https://www.globenewswire.com/news-release/2026/02/26/3245409/0/en/Upstream-Bio-to-Present-Additional-Analyses-from-Phase-2-VIBRANT-Trial-in-Chronic-Rhinosinusitis-with-Nasal-Polyps-in-Late-Breaking-Session-at-AAAAI-Annual-Meeting-2026.html
Context: Upstream Bio said the late-breaking AAAAI 2026 presentation covers additional analyses from the Phase 2 VIBRANT trial in chronic rhinosinusitis with nasal polyps, including adjustment for concomitant rescue therapy use [2].
Key point: Upstream Bio announced an upcoming poster on efficacy and safety of verekitug (UPB-101) in CRSwNP, based on additional Phase 2 analyses [2].
Implication: May influence prescriber choice and payer reviews pending full data.

💉 SK bioscience, IDT Biologika, Vaxxas win EU-backed influenza patch vaccine project [3] [EU • 26 Feb 2026]

https://www.prnewswire.com/news-releases/sk-bioscience-idt-biologika-and-vaxxas-selected-for-next-generation-influenza-vaccine-development-financed-by-the-european-union-302697969.html
Context: The consortium was selected under an EU-managed framework contract for next-generation vaccines, with Phase 1 funding support and a planned Phase 1 clinical trial [3].
Key point: SK bioscience, IDT Biologika, and Vaxxas said they were selected to develop seasonal and pandemic influenza vaccines using high-density microarray patch (HD-MAP) delivery [3].
Implication: Partnerships/BD: Signals pipeline investment and modality expansion.

🌬️ GLP-1 receptor agonists linked to fewer asthma exacerbations in obese patients [4] [27 Feb 2026]

https://respiratory-therapy.com/disorders-diseases/chronic-pulmonary-disorders/asthma/glp-1s-tied-to-reduced-asthma-exacerbation-in-obese-patients/
Context: The AAAAI 2026 analysis used TriNetX data in overweight, obese, and morbidly obese non-diabetic asthma patients, with three-year matched-cohort comparisons [4].
Key point: Investigators reported GLP-1 initiation was associated with lower asthma exacerbation risk across BMI-defined cohorts in this observational analysis [4].
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🧒 Asthma biologics not linked to higher respiratory infection risk in pediatric real-world study [5] [US • 02 Mar 2026]

https://respiratory-therapy.com/disorders-diseases/chronic-pulmonary-disorders/asthma/asthma-biologics-respiratory-infections/
Context: A retrospective matched cohort study used the TriNetX US Collaborative Network in children with moderate to severe persistent asthma receiving standard background therapy [5].
Key point: Researchers reported no increased respiratory infection risk with asthma biologics overall, with lower pneumonia probability seen for dupilumab and anti-IL-5 agents in the study [5].
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🫀 United Therapeutics says ralinepag met Phase 3 endpoint in PAH [6] [US • 02 Mar 2026]

https://ir.unither.com/press-releases/2026/03-02-2026-113011187
Context: The pivotal Phase 3 ADVANCE OUTCOMES study enrolled predominantly pre-treated pulmonary arterial hypertension patients, with 80% on dual background therapy [6].
Key point: United Therapeutics said ralinepag reduced the risk of clinical worsening versus placebo in PAH and met several secondary endpoints, with an NDA planned in 2H 2026 [6].
Implication: May influence prescriber choice and payer reviews pending full data.

🧪 bioAffinity Technologies presents sputum-based asthma therapy-matching platform data [7] [US • 03 Mar 2026]

https://www.pharmiweb.com/press-release/2026-03-03/bioaffinity-technologies-presents-positive-research-findings-for-its-novel-diagnostic-platform-technology-to-identify-optimal-therapies-for-asthma-patients
Context: The poster was presented at AAAAI 2026 and described use of sputum and flow cytometry with automated AI analysis to identify antibody drug receptors [7].
Key point: bioAffinity Technologies said its diagnostic platform identified receptors in sputum for dupilumab and benralizumab, aiming to support therapy selection in asthma (and potentially COPD) [7].
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🫁 Rein Therapeutics doses first Phase 2 patient for LTI-03 in IPF [8] [US • 03 Mar 2026]

https://ir.reintx.com/news-releases/news-release-details/rein-therapeutics-doses-first-patient-phase-2-trial-lti-03
Context: The randomized, double-blind, placebo-controlled Phase 2 study is designed to assess safety, tolerability, and lung function/structure impact, with approximately 120 patients planned across five countries [8].
Key point: Rein Therapeutics announced first-patient dosing in its Phase 2 trial of inhaled LTI-03 for idiopathic pulmonary fibrosis after FDA clearance to resume the program [8].
Implication: May influence prescriber choice and payer reviews pending full data.

🦠 BioVersys publishes BV100 Phase 1 data, advances registrational program in MDR infections [9] [Switzerland • 04 Mar 2026]

https://www.biospace.com/press-releases/bioversys-announces-publication-of-bv100-phase-1-clinical-data-in-journal-of-antimicrobial-agents-and-chemotherapy
Context: BioVersys said BV100 is an intravenous rifabutin formulation for multidrug-resistant Acinetobacter baumannii infections; the company also described ongoing Phase 3 and planned Phase 2b studies [9].
Key point: BioVersys reported published Phase 1 pharmacokinetic, safety, and tolerability data showing BV100 was generally safe, well tolerated, and dose-proportional [9].
Implication: May influence prescriber choice and payer reviews pending full data.

Why it matters

Pulmonary arterial hypertension was a major theme this week, with mixed Phase 3 data for seralutinib and a positive pivotal readout for ralinepag, both pointing to continued competition in PAH [1][6].
AAAAI-linked items dominated the allergy and asthma segment, spanning biologics safety, observational GLP-1 findings, CRSwNP biologic analyses, and diagnostic stratification tools [2][4][5][7].
Respiratory innovation is broadening beyond therapeutics into diagnostics and delivery platforms, including sputum-based therapy matching and HD-MAP influenza vaccines [3][7].
Early- to mid-stage pipeline execution continues in fibrosis and anti-infectives, with first-patient dosing for LTI-03 in IPF and continued late-stage planning for BV100 [8][9].

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 See the full Respiratory archive on our research hub page

FAQ

What happened in Gossamer Bio’s PROSERA trial for seralutinib?

Gossamer Bio reported that seralutinib improved six-minute walk distance versus placebo in Phase 3 PROSERA, but the overall primary endpoint missed the prespecified alpha threshold. The company said it plans to discuss the path forward with the FDA [1].

What did United Therapeutics report for ralinepag?

United Therapeutics said the Phase 3 ADVANCE OUTCOMES study met its primary endpoint, with ralinepag reducing risk of clinical worsening in PAH. The company plans a U.S. NDA submission in the second half of 2026 [6].

What is Upstream Bio presenting for verekitug?

Upstream Bio said it would present additional analyses from the Phase 2 VIBRANT trial in CRSwNP at AAAAI 2026, including efficacy analyses adjusted for rescue therapy use. The source pack did not include the exact URL [2].

Did asthma biologics raise infection risk in the pediatric study?

No increased respiratory infection risk was reported overall in the TriNetX-based retrospective analysis. Dupilumab and anti-IL-5 agents were associated with lower pneumonia risk within the study [5].

What is Rein Therapeutics testing with LTI-03?

Rein is evaluating inhaled LTI-03 in a randomized, placebo-controlled Phase 2 trial in idiopathic pulmonary fibrosis, with safety, tolerability, and lung-function measures included. First-patient dosing was announced on 03 Mar 2026 [8].

What is BioVersys doing with BV100 now?

BioVersys announced publication of BV100 Phase 1 data and said its global Phase 3 program is underway, with an additional Phase 2b trial planned in 2026. BV100 targets MDR Acinetobacter baumannii infections [9].

Entities / Keywords

Gossamer Bio, seralutinib, PROSERA, TORREY, pulmonary arterial hypertension (PAH), six-minute walk distance (6MWD)
Upstream Bio, verekitug, UPB-101, VIBRANT, chronic rhinosinusitis with nasal polyps (CRSwNP), TSLP receptor
SK bioscience, IDT Biologika, Vaxxas, HD-MAP, influenza vaccine, seasonal influenza, pandemic influenza, HERA, HaDEA
GLP-1 receptor agonists, asthma exacerbation, obesity, TriNetX, AAAAI
Dupilumab, omalizumab, anti-IL-5, tezepelumab, pediatric asthma, respiratory infections, pneumonia
United Therapeutics, ralinepag, ADVANCE OUTCOMES, PAH, clinical worsening, NDA
bioAffinity Technologies, sputum diagnostics, dupilumab receptor, benralizumab receptor, asthma, COPD
Rein Therapeutics, LTI-03, idiopathic pulmonary fibrosis (IPF), Phase 2, FVC
BioVersys, BV100, rifabutin, Acinetobacter baumannii, CRAB, VABP, HABP, RIV-TARGET, RIV-CARE